Thermo Fisher Scientific, Inc. (TMO) has recently unveiled a cutting-edge instrument to amplify the adaptability, efficiency, and reliability of laboratories. The newly launched Thermo Scientific Dionex Inuvion Ion Chromatography (IC) system is poised to simplify ion analysis for labs of various sizes and reinforce the company’s Analytical Instrument segment.
Breaking Down the New Launch
The Dionex Inuvion system paves the way for more effective laboratory operations by offering easily adjustable workflows and a compact footprint. With its flexible platform, the system can be tailored to meet current analytical needs while also enabling better adaptation to evolving sample types and workflow requirements in the future, in a more cost-effective manner.
The Dionex Inuvion IC system incorporates user-friendly design enhancements to improve operator experience and allows user-installable accessories for expanding system capabilities, ultimately contributing to the achievement of superior quality results. The system features advanced pump technology, enhancing speed, quality, and reproducibility.
Enhanced Laboratory Functionality
Aligned with Thermo Fisher’s commitment to empowering its clients to create a safer, cleaner, and healthier world, the Dionex Inuvion IC system equips industrial, municipal water, food and beverage, and environmental labs with the necessary tools for identifying ionic pollutants in water. Furthermore, it ensures quality control for tiny ionic compounds in food, beverage, and pharmaceutical products and aids in identifying corrosive pollutants in oil and gas.
Drawing on years of experience, the Dionex Inuvion system expands the capabilities of laboratories of all sizes, streamlining its IC portfolio so that labs can readily access technology best suited to their needs. With its easily reconfigurable design, this new analytical equipment offers a one-stop shop for consistent and reliable ion analysis, catering to the needs of individuals seeking to identify ionic and tiny polar substances.
Industry Prospects
According to a report by Mordor Intelligence, the global chromatography instrumentation market size is projected to reach $9.63 billion by 2024 and $12.42 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.23%. The market’s growth is driven by the increasing applications of chromatography in various sectors, including pharmaceuticals, chemicals, food, environmental testing, and forensic science, as well as the rising adoption of chromatography techniques in the drug discovery process.
Recent Developments
In December 2023, Thermo Fisher launched CorEvidence, a proprietary cloud-based data lake platform aimed at optimizing pharmacovigilance case processing and safety data management processes. This platform, tailored to tackle some of the most challenging and complex pharmacovigilance business needs, demonstrates the company’s commitment to innovation and addressing industry demands.
During the same period, Thermo Fisher entered into an exclusive distribution agreement with Aesku. Group (“Aesku”) to market, sell, and support their portfolio of FDA-cleared IFA products, automated instruments, and software in the United States. This strategic partnership positions Thermo Fisher to provide US laboratories with a full suite of automated diagnostic tools and procedures.
Price Performance
In the last six months, TMO’s shares have gained 3.1%, compared with the industry’s 8.1% rise.
Zacks Rank and Key Picks
Thermo Fisher currently holds a Zacks Rank #3 (Hold).
Noteworthy stocks in the broader medical space include Stryker Corporation (SYK), Cencora, Inc. (COR), and Cardinal Health (CAH).
Stryker, carrying a Zacks Rank #2 (Buy), reported adjusted EPS of $3.46 in the fourth quarter of 2023, surpassing the Zacks Consensus Estimate by 5.8% and outpacing revenue estimates.
Cencora, with a Zacks Rank #2, reported an adjusted EPS of $3.28 in the first quarter of fiscal 2024, beating revenue estimates by 5.1%.
Cardinal Health, also sporting a Zacks Rank #2, reported second-quarter fiscal 2024 adjusted earnings of $1.82, beating revenue estimates by 1.1%.
The information does not constitute investment advice or an endorsement of the products listed. The views and opinions expressed do not necessarily reflect those of Nasdaq, Inc.
